長庚大學

研究方向及研究室特色:

核心研究方向

1.癌症合併免疫治療與腫瘤原位疫苗開發（癌症免疫治療及原位疫苗接種）研究重點：聚焦微環境調控，利用新型佐劑開發腫瘤原位疫苗接種或結合新療法疫苗。核心機制：探討如何活化腫瘤微環境（TME）中的免疫細胞，打破實體的腫瘤免疫耐受性，並與免疫檢查點配對（如抗PD-1）產生強效的協同效應（協同效應），以提升癌細胞的治療效果。

2.慢性發炎與器官纖維化之分子機制與新藥開發 (Inflammatory & Fibrotic Disease Therapeutics)研究重點：針對發炎相關結直腸癌（CAC）、潰瘍性結腸炎與器官纖維化（如腎纖維化），探索致病關鍵之保護蛋白（如 LTBP4）與特殊離子通道（如 Pannexin 1）。核心機制：透過新型小分子藥物或奈米緩釋劑型，調控組織微環境中的粒線體功能、血管新生與發炎反應，開發兼具疾病防禦與組織修復潛力的多功能標靶療法。

研究室特色

1.一站式核心技術培訓：融合「細胞實驗」與「動物模型」雙軌訓練，帶你完整走過藥物從細胞測試到動物體內驗證的過程。

2.解鎖實驗技能：獨立操作分子生物學實驗，並掌握免疫學技術，培養帶得走的跨領域研究能力。

3.高含量的轉譯醫學實務：實驗室支持您探索具備臨床醫療潛力的前沿課題。

最近五年所發表論文: (*, Corresponding author):

1.Shin-Yun Liu , Chia-Lang Hsu , Shih-Feng Yang , Hsuan-Shu Lee , Jin-Chuan Sheu , Meng-Tzu Weng. Intratumoral administration of poly-ICLC enhances the antitumor effects of anti-PD-1.J Hepatobiliary
Pancreat Sci. 2025 Feb;32(2):139-150. (第一作者，IF 3.2)

2.Meng-Tzu Weng , Shin-Yun Liu , Chia-Yueh Hsiung , Meng-Chuan Wu , Tsung-Ying Lee , Been-Ren Lin , Yun-Ching Chen , Shu-Chen Wei. SN38 PLGA nanoparticles provide sustained antitumor efficacy and ameliorate colitis severity in a murine colitis-associated cancer model. International Journal of Pharmaceutics: X\ Volume 11, June 2026, 100552 （IF 7.9 ）

3.Wen-Yun Hsueh, Yi-Ling Wu, Meng-Tzu Weng, Shin-Yun Liu, Jascinta P Santavanond, Yi-Chung Liu, Ching-I Lin, Cheng-Nong Lai, Yi-Ru Lu, Jing Yin Hsu, Hong-Yu Gao,Jinq-Chyi Lee, Shu-Chen Wei, Ping-Chiang Lyu, Ivan K H Poon, Hsing-Pang Hsieh,*and Yu-Hsin Chiu. Novel Naphthyridones Targeting Pannexin 1 for Colitis Management. Adv Sci (Weinh). 2025 Feb;12(7):e2411538. (IF 14.6)

4.Chi-Ting Su, Daniel H.W. See, Yue-Jhu Huang,Tzu-Ming Jao, Shin-Yun Liu , Chih-Yi Chou , Chun-Fu Lai, Wei-Chou Lin, Chih-Yuan Wang, Jenq-Wen Huang, Kuan-Yu Hung. LTBP4 (Latent Transforming Growth
Factor Beta Binding Protein 4) Protects Against Renal Fibrosis via Mitochondrial and Vascular Impacts. Circulation Research 2023;133:71-85. (IF 18)

5.Shih-Feng Yang, Meng-Tzu Weng, Ja-Der Liang, Ling-Ling Chiou, Yu-Chen Hsu, Ying-Te Lee, Shin-Yun Liu, Meng-Chuan Wu, Huei-Chi Chou, Li-Fang Wang, Shu-Han Yu, Hsuan-Shu Lee, Jin-Chuan Sheu. Neoantigen vaccination augments antitumor effects of anti-PD-1 on mouse hepatocellular carcinoma. Cancer Letters 2023 April 18 Volume 563.(IF 10.1)

6. Meng-Tzu Weng, Shih-Feng Yang, Shin-Yun Liu, Yu-Chen Hsu, Meng-Chuan Wu, Huei-Chi Chou, Ling-Ling Chiou, Ja-Der Liang, Li-Fang Wang, Hsuan-Shu Lee, Jin-Chuan Sheu. In situ vaccination followed by intramuscular poly-ICLC injections for the treatment of hepatocellular carcinoma in mouse models. Pharmacological Research 4 January 2023 Volume 188, 2023. (IF 10.5)

7. Maria Janina Carrera Espinoza, Kuen-Song Lin*, Meng-Tzu Weng*, Sikhumbuzo Charles Kunene, You-Sheng Lin, Shin-Yun Liu. Magnetic boron nitride nanosheets-based on pH-responsive smart nanocarriers for the delivery of doxorubicin for liver cancer treatment. Colloids and Surfaces B: Biointerfaces 3 January 2023 Volume 222, 2023, 113129.(*corresponding author, IF 5.6)

8. Ndumiso Vukile Mdlovu, Kuen-Song Lin,* , Meng-Tzu Weng*, You-Sheng Lin, Shin-Yun Liu. Preparation and in-vitro/in-vivo evaluation of doxorubicin-loaded magnetic SBA-15 nanocomposites from rice husk for enhancing therapeutic efficacy. Colloids and Surfaces B:Biointerfaces 10 October 2022 Volume 220, 2022, 112923.( *corresponding author, IF 5.6)

9. Maria Janina Carrera Espinoza, Kuen-Song Lin, Meng-Tzu Weng, Sikhumbuzo Charles Kunene, Shin-Yun Liu, You-Sheng Lin. In vivo and in vitro studies of magnetic silicananocomposites decorated with Pluronic F127 for controlled drug delivery system. Journal of Industrial and Engineering Chemistry 25 November 2022, Volume 115, Pages 510-520. (IF 5.9)

生物醫學研究所

劉心雲 / Shin Yun Liu

研究方向及研究室特色:

最近五年所發表論文: (*, Corresponding author):